Wednesday, 13 Dec 2017

You are here

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on 

  1. FDA accepts Pfizers NDA for Xeljanz (tofacitinib) as treatment for moderately to severely active ulcerative colitis
  2. FDA rejects Romosuzumab (anti-Sclerostin OP Rx) w/ a complete response letter asking for resubmission, more data
  3. RA ACPA+ have higher economic burden with MORE early DMARD use (71 vs 50%) & Biologic use (20 vs 12%); more MD visits; & more Total costs
  4. Mucosal immunity seen in at-risk RA (preclinical) people who had more IgA producing plasmablasts (39%) than established RA or normal controls(1%, 9%) 
  5. 7 patients with Active Refractory Takayasu arteritis treated with RTX showed mixed results - 3 achieved remission but 4 failed to respond to RTX.  
  6. Study of 38,924 shows dairy intake assoc with an increased risk of OA hip replacement (unrelated to age, BMI, smoking, activity
  7. 1979-2013 Septic arthritis in RA has increased and associated with more biologic use, polyarticular infections, MRSA (6% v 31%); but same outcomes
  8. Alcohol & Smoking assoc w/ 2 fold risk of Hand OA. but being overweight or obese is NOT.
  9. MTX has yet to be shown to benefit Osteoarthritis; but there is a new PROMOTE trial looking at pain reduction. Still enrolling.
  10. Zurampic 200mg + Uloric fails vs Uloric alone at achieving two primary endpoints SUA<5 (57% vs 47%) & topus resolution (no diff btw groups).
  11. Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too 
  12. Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis 
  13. Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus 
  14. FDA Approves Tremfya (guselkumab) for Plaque Psoriasis


Rheumatologists' Comments

Decades ago waited 12 weeks to diagnose RA. Now can think pre RA Great! Anticipating more in shorter time frame.

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.